Metraipolis › archive › dc_6e5cb1fc2133

Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers — Europe PMC PMID:42076098

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42076098
DOI
10.3390/pharmaceutics18040446
License (as archived)
solo-consultazione
Archived
2026-11-03T08:56:32.010Z
SHA-256 of the archived text
1882055f7095957b6ad5810002d92bcb45de24df119cdaf8f70b2ee5646fc903
Stable URL of this page
https://metraipolis.com/documento/dc_6e5cb1fc2133

How to cite

Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers — Europe PMC PMID:42076098 — Europe PMC (en), https://europepmc.org/article/MED/42076098 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6e5cb1fc2133 (Metraipolis archive dc_6e5cb1fc2133, sha256 1882055f7095957b6ad5810002d92bcb45de24df119cdaf8f70b2ee5646fc903)
BibTeX
@misc{dc6e5cb1fc2133,
  title = {Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers — Europe PMC PMID:42076098},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42076098},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6e5cb1fc2133; sha256 1882055f7095957b6ad5810002d92bcb45de24df119cdaf8f70b2ee5646fc903},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42076098. Agents can read the archived copy with the MCP tool read_document.